Many of the antiplatelet drugs are effective and useful in coronary disease but when it comes to the cerebral vascular diseases or stroke, heparin3,4 and antiplatelet drugs, GPIIb/IIIa inhibitors like abciximab5 or tirofiban6,7, P2Y12 blockers such as prasugrel8 or the thrombin-receptor antagonist vorapaxar9 cause treatment-induce bleedings and they are contraindicated in stroke. This evidence concerns the gene F2R and stroke disorder.